Diabetes mellitus exacerbates motor and sensory impairment in CMT1A: Research report

Journal of the Peripheral Nervous System

Volumn 13, Issue 4, 2008, Pages 299-304

  Sheth, Soham ^a   Francies, Kevin ^a   Siskind, Carly E ^a   Feely, Shawna M E ^a   Lewis, Richard A ^a   Shy, Michael E ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CMT; CMT1A; Diabetes; Neuropathy

Indexed keywords

ADULT; ARTICLE; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE EXACERBATION; FEMALE; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; MALE; MEDIAN NERVE; MOTOR NERVE CONDUCTION; PRIORITY JOURNAL; SENSORY NERVE CONDUCTION; ULNAR NERVE;

ACTION POTENTIALS; ADULT; CHARCOT-MARIE-TOOTH DISEASE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; ELECTROPHYSIOLOGY; FEMALE; HUMANS; MALE; NEURAL CONDUCTION;

EID: 58449116120     PISSN: 10859489     EISSN: 15298027     Source Type: Journal    
DOI: 10.1111/j.1529-8027.2008.00196.x     Document Type: Article

References (26)

1. Bach D, Naon D, Pich S, Soriano FX, Vega N, Rieusset J, Laville M, Guillet C, Boirie Y, Wallberg-Henriksson H, Manco M, Calvani M, Castagneto M, Palacin M, Mingrone G, Zierath JR, Vidal H, Zorzano A (2005). Expression of Mfn2, the Charcot-Marie-Tooth neuropathy type 2A gene, in human skeletal muscle: effects of type 2 diabetes, obesity, weight loss, and the regulatory role of tumor necrosis factor alpha and interleukin-6. Diabetes 54 : 2685 2693.
2. Birouk N, Gouider R, Le Guern E, Gugenheim M, Tardieu S, Maisonobe R, Le Forestier N, Agid Y, Brice A, Bouche P (1997). Charcot-Marie-Tooth disease type 1A with 17p11.2 duplication. Clinical and electrophysiological phenotype study and factors influencing disease severity in 119 cases. Brain 120 : 813 823.
3. Celik M, Forta H, Parman Y, Bissar-Tadmouri N, Demirkirkan K, Battaloglu E (2001). Charcot-Marie-Tooth disease associated with type 2 diabetes mellitus. Diabet Med 18 : 685 686.
4. Chung KW, Kim SB, Park KD, Choi KG, Lee JH, Eun HW, Suh JS, Hwang JH, Kim WK, Seo BC, Kim SH, Son IH, Kim SM, Sunwoo IN, Choi BO (2006). Early onset severe and late-onset mild Charcot-Marie-Tooth disease with mitofusin 2 (MFN2) mutations. Brain 129 : 2103 2118.
5. Cornblath DR, Chaudhry V, Carter K, Lee D, Seysedadr M, Miernicki M, Joh T (1999). Total neuropathy score: validation and reliability study. Neurology 53 : 1660 1664.
6. Dyck PJ (1975). Inherited neuronal degeneration and atrophy affecting peripheral motor, sensory and autonomic neurons. In : Peripheral Neuropathy. Dyck PJ, Lambert EH (Eds). W.B. Saunders, Philadelphia, pp 825.
7. Harding AE, Thomas PK (1980). The clinical features of hereditary motor and sensory neuropathy types I and II. Brain 103 : 259 280.
8. Huxley C, Passage E, Manson A, Putzu G, Figarella-Branger D, Pellissier JF, Fontes M (1996). Construction of a mouse model of Charcot-Marie-Tooth disease type 1A by pronuclear injection of human YAC DNA. Hum Mol Genet 5 : 563 569.
9. Krajewski KM, Lewis RA, Fuerst DR, Turansky C, Hinderer SR, Garbern J, Kamholz J, Shy ME (2000). Neurological dysfunction and axonal degeneration in Charcot-Marie-Tooth disease type 1A. Brain 123 : 1516 1527.
10. Leinninger GM, Edwards JL, Lipshaw MJ, Feldman EL (2006). Mechanisms of disease: mitochondria as new therapeutic targets in diabetic neuropathy. Nat Clin Pract Neurol 2 : 620 628.
11. Llewelyn, JG, Tomlinson DR, Thomas PK (2005). Diabetic neuropathies. In : Peripheral Neuropathy. Dyck PJ, Thomas PK (Eds). Elsevier Saunders, Philadelphia, pp 1951 1991.
12. Lupski JR, de Oca-Luna RM, Slaugenhaupt S, Pentao L, Guzzetta V, Trask BJ, Saucedo-Cardenas O, Barker DF, Killian JM, Garcia CA, Chakravarti A, Patel PI (1991). DNA duplication associated with Charcot-Marie-Tooth disease type 1A. Cell 66 : 219 232.
13. Nelis E, Van Broeckhoven C, De Jonghe P, Lofgren A, Vandenberghe A, Latour P, Le Guern E, Brice A, Mostacciuolo ML, Schiavon F, Palau F, Bort S, Upadhyaya M, Rocchi M, Archidiacono N, Mandich P, Bellone E, Silander K, Savontaus ML, Navon R, Goldberg-Stern H, Estivill X, Volpini V, Friedl W, Gal A (1996). Estimation of the mutation frequencies in Charcot-Marie-Tooth disease type 1 and hereditary neuropathy with liability to pressure palsies: a European collaborative study. Eur J Hum Genet 4 : 25 33.
14. Ota T, Osawa K (2003). Marked improvement of glycaemic control with pioglitazone in a type 2 diabetic patient associated with Charcot-Marie-Tooth disease. Diabet Med 20 : 420 421.
15. Raeymaekers P, Timmerman V, Nelis E, De Jonghe P, Hoogendijk JE, Baas F, Barker DF, Martin JJ, De Visser M, Bolhuis PA, Van Broeckhoven C HMSN Collaborative Research Group (1991). Duplication in chromosome 17p11.2 in Charcot-Marie-Tooth neuropathy type 1a (CMT 1a). The HMSN Collaborative Research Group. Neuromuscul Disord 1 : 93 97.
16. Schiller Y, Rahamimoff R (1989). Neuromuscular transmission in diabetes: response to high-frequency activation. J Neurosci 9 : 3709 3719.
17. Sereda M, Griffiths I, Puhlhofer A, Stewart H, Rossner MJ, Zimmerman F, Magyar JP, Schneider A, Hund E, Meinck HM, Suter U, Nave KA (1996). A transgenic rat model of Charcot-Marie-Tooth disease. Neuron 16 : 1049 1060.
18. Shy ME, Blake J, Krajewski K, Fuerst DR, Laura M, Hahn AF, Li J, Lewis RA, Reilly M (2005). Reliability and validity of the CMT neuropathy score as a measure of disability. Neurology 64 : 1209 1214.
19. Shy ME, Chen L, Swan ER, Taube R, Krajewski KM, Herrmann D, Lewis RA, McDermott MP (2008). Neuropathy progression in Charcot-Marie-Tooth disease type 1A. Neurology 70 : 378 383.
20. Skre H (1974). Genetic and clinical aspects of Charcot-Marie-Tooth's disease. Clin Genet 6 : 98 118.
21. Soriano FX, Liesa N, Bach D, Chan DC, Palacin M, Zorzano A (2006). Evidence for a mitochondrial regulatory pathway defined by peroxisome proliferator-activated receptor-gamma coactivator-1 alpha, estrogen-related receptor-alpha, and mitofusin 2. Diabetes 55 : 1783 1791.
22. Thomas PK, Marques W Jr., Davis MB, Sweeney MG, King RH, Bradley JL, Muddle JR, Tyson J, Malcolm S, Harding AE (1997). The phenotypic manifestations of chromosome 17p11.2 duplication. Brain 120 : 465 478.
23. Verhoeven K, Claeys KG, Züchner S, Schröder JM, Weis J, Ceuterick C, Jordanova A, Nelis E, De Vriendt E, Van Hul M, Seeman P, Mazanec R, Saifi GM, Szigeti K, Mancias P, Butler IJ, Kochanski A, Ryniewicz B, De Bleecker J, Van den Bergh P, Verellen C, Van Coster R, Goemans N, Auer-Grumbach M, Robberecht W, Milic Rasic V, Nevo Y, Tournev I, Guergueltcheva V, Roelens F, Vieregge P, Vinci P, Moreno MT, Christen HJ, Shy ME, Lupski JR, Vance JM, De Jonghe P, Timmerman V (2006). MFN2 mutation distribution and genotype/phenotype correlation in Charcot-Marie-Tooth type 2. Brain 129 : 2093 2102.
24. Weimer LH, Podwall D (2006). Medication-induced exacerbation of neuropathy in Charcot Marie Tooth disease. J Neurol Sci 242 : 47 54.
25. Wrabetz L, Feltri ML, Quattrini A, Imperiale D, Previtali S, D'Antonio M, Martini R, Yin X, Trapp BD, Zhou L, Chiu SY, Messing A (2000). P(0) glycoprotein overexpression causes congenital hypomyelination of peripheral nerves. J Cell Biol 148 : 1021 1034.
26. Zuchner S, Mersiyanova IV, Muglia M, Bissar-Tadmouri N, Rochelle J, Dadali EL, Zappia M, Nelis E, Patitucci A, Senderek J, Parman Y, Evgrafov O, Jonghe PD, Takahashi Y, Tsuji S, Pericak-Vance MA, Quattrone A, Battaloglu E, Polyakov AV, Timmerman V, Schröder JM, Vance JM (2004). Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A. Nat Genet 36 : 449 451.